Recombinant viral capsid protein VP1 suppresses migration and invasion of human cervical cancer by modulating phosphorylated prohibitin in lipid rafts

Cancer Letters

Volumn 320, Issue 2, 2012, Pages 205-214

  Chiu, Ching Feng ^a,b   Peng, Jei Ming ^c   Hung, Shao Wen ^b   Liang, Chi Ming ^c   Liang, Shu Mei ^a,b,c  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b AGRICULTURAL BIOTECHNOLOGY RESEARCH CENTER   (Taiwan)

^c GENOMICS RESEARCH CENTER   (Taiwan)

Author keywords

Cancer metastasis; PIP3; Prohibitin; Raf 1; RVP1

Indexed keywords

GELATINASE A; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PROHIBITIN; PROTEIN KINASE B; PROTEIN VP1; RAF PROTEIN; RECOMBINANT VIRAL CAPSID PROTEIN VP1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL INVASION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID RAFT; LIVER METASTASIS; LUNG METASTASIS; METASTASIS INHIBITION; MIGRATION INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; SURVIVAL TIME; TUMOR XENOGRAFT; UTERINE CERVIX CANCER;

ANIMALS; CAPSID PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; HUMANS; MICE; MICE, SCID; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PHOSPHATIDYLINOSITOL PHOSPHATES; PHOSPHORYLATION; RAF KINASES; RECOMBINANT PROTEINS; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; UTERINE CERVICAL NEOPLASMS;

FOOT-AND-MOUTH DISEASE VIRUS; MIRIDAE;

EID: 84859587304     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.02.027     Document Type: Article

References (40)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2011, 127:2893-2917.
2. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
3. Sleeman J., Steeg P.S. Cancer metastasis as a therapeutic target. Eur. J. Cancer 2010, 46:1177-1180.
4. Gupta G.P., Massague J. Cancer metastasis: building a framework. Cell 2006, 127:679-695.
5. Argenta P.A., Ghebre R., Dusenbery K.E., Chen M.D., Judson P.L., Downs L.S., Carson L.F. Radiation therapy with concomitant and adjuvant cisplatin and paclitaxel in high-risk cervical cancer: long-term follow-up. Eur. J. Gynaecol. Oncol. 2006, 27:231-235.
6. van Regenmortel M.H., Mayo M.A., Fauquet C.M., Maniloff J. Virus nomenclature: consensus versus chaos. Arch. Virol. 2000, 145:2227-2232.
7. Belsham G.J. Distinctive features of foot-and-mouth disease virus, a member of the picornavirus family; aspects of virus protein synthesis, protein processing and structure. Prog. Biophys. Mol. Biol. 1993, 60:241-260.
8. Ruiz-Saenz J., Goez Y., Tabares W., Lopez-Herrera A. Cellular receptors for foot and mouth disease virus. Intervirology 2009, 52:201-212.
9. Peng J.M., Liang S.M., Liang C.M. VP1 of foot-and-mouth disease virus induces apoptosis via the Akt signaling pathway. J. Biol. Chem. 2004, 279:52168-52174.
10. Chen T.A., Wang J.L., Hung S.W., Chu C.L., Cheng Y.C., Liang S.M. Recombinant VP1, an Akt inhibitor, suppresses progression of hepatocellular carcinoma by inducing apoptosis and modulation of CCL2 production. PLoS ONE 2011, 6:e23317.
11. Peng J.M., Chen Y.H., Hung S.W., Chiu C.F., Ho M.Y., Lee Y.J., Lai T.C., Hsiao M., Liang C.M., Liang S.M. Recombinant viral protein promotes apoptosis and suppresses invasion of ovarian adenocarcinoma cells by targeting alpha5beta1 integrin to down-regulate Akt and MMP-2. Br. J. Pharmacol. 2012, 165:479-493.
12. Karnoub A.E., Weinberg R.A. Ras oncogenes: split personalities. Nat. Rev. Mol. Cell Biol. 2008, 9:517-531.
13. Nock N.L., Berger N.A. Obesity and cancer: overview of mechanisms. Cancer and Energy Balance, Epidemiology and Overview 2010, 129-179. Springer Science+Business Media, New York, USA. N.A. Berger (Ed.).
14. Zhang X.Y., Zhang H.Y., Zhang P.N., Lu X., Sun H. Elevated phosphatidylinositol 3-kinase activation and its clinicopathological significance in cervical cancer. Eur. J. Obstet. Gynecol. Reprod. Biol. 2008, 139:237-244.
15. Maurer G., Tarkowski B., Baccarini M. Raf kinases in cancer-roles and therapeutic opportunities. Oncogene 2011, 30:3477-3488.
16. Rajalingam K., Wunder C., Brinkmann V., Churin Y., Hekman M., Sievers C., Rapp U.R., Rudel T. Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell migration. Nat. Cell Biol. 2005, 7:837-843.
17. Rajalingam K., Rudel T. Ras-Raf signaling needs prohibitin. Cell Cycle 2005, 4:1503-1505.
18. Dhillon A.S., Meikle S., Yazici Z., Eulitz M., Kolch W. Regulation of Raf-1 activation and signalling by dephosphorylation. EMBO J. 2002, 21:64-71.
19. Zimmermann S., Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 1999, 286:1741-1744.
20. Patel N., Chatterjee S.K., Vrbanac V., Chung I., Mu C.J., Olsen R.R., Waghorne C., Zetter B.R. Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells. Proc. Natl. Acad. Sci. USA 2010, 107:2503-2508.
21. Mishra S., Murphy L.C., Murphy L.J. The Prohibitins: emerging roles in diverse functions. J. Cell Mol. Med. 2006, 10:353-363.
22. Kolonin M.G., Saha P.K., Chan L., Pasqualini R., Arap W. Reversal of obesity by targeted ablation of adipose tissue. Nat. Med. 2004, 10:625-632.
23. Terashima M., Kim K.M., Adachi T., Nielsen P.J., Reth M., Kohler G., Lamers M.C. The IgM antigen receptor of B lymphocytes is associated with prohibitin and a prohibitin-related protein. EMBO J. 1994, 13:3782-3792.
24. Han E.K., McGonigal T., Butler C., Giranda V.L., Luo Y. Characterization of Akt overexpression in MiaPaCa-2 cells: prohibitin is an Akt substrate both in vitro and in cells. Anticancer Res. 2008, 28:957-963.
25. Ande S.R., Gu Y., Nyomba B.L., Mishra S. Insulin induced phosphorylation of prohibitin at tyrosine 114 recruits Shp1. Biochim. Biophys. Acta 2009, 1793:1372-1378.
26. Wang J.H., Liang C.M., Peng J.M., Shieh J.J., Jong M.H., Lin Y.L., Sieber M., Liang S.M. Induction of immunity in swine by purified recombinant VP1 of foot-and-mouth disease virus. Vaccine 2003, 21:3721-3729.
27. Huang Q., Shen H.M., Shui G., Wenk M.R., Ong C.N. Emodin inhibits tumor cell adhesion through disruption of the membrane lipid Raft-associated integrin signaling pathway. Cancer Res. 2006, 66:5807-5815.
28. Lee M.Y., Shen M.R. Epithelial-mesenchymal transition in cervical carcinoma. Am. J. Trans. Res. 2012, 4:1-13.
29. Liotta L.A., Stetler-Stevenson W.G. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res. 1991, 51:5054s-5059s.
30. Sievers C., Billig G., Gottschalk K., Rudel T. Prohibitins are required for cancer cell proliferation and adhesion. PLoS ONE 2010, 5:e12735.
31. Wang S., Nath N., Fusaro G., Chellappan S. Rb and prohibitin target distinct regions of E2F1 for repression and respond to different upstream signals. Mol. Cell. Biol. 1999, 19:7447-7460.
32. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657.
33. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
34. Yuan T.L., Cantley L.C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27:5497-5510.
35. Calay D., Vind-Kezunovic D., Frankart A., Lambert S., Poumay Y., Gniadecki R. Inhibition of Akt signaling by exclusion from lipid rafts in normal and transformed epidermal keratinocytes. J. Invest. Dermatol. 2010, 130:1136-1145.
36. Friday B.B., Adjei A.A. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin. Cancer Res. 2008, 14:342-346.
37. Leicht D.T., Balan V., Kaplun A., Singh-Gupta V., Kaplun L., Dobson M., Tzivion G. Raf kinases: function, regulation and role in human cancer. Biochim. Biophys. Acta 2007, 1773:1196-1212.
38. Roberts P.J., Der C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26:3291-3310.
39. Overall C.M., Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer 2002, 2:657-672.
40. Zhang D., Bar-Eli M., Meloche S., Brodt P. Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals. J. Biol. Chem. 2004, 279:19683-19690.